Skip to search formSkip to main contentSkip to account menu

octapharma

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
DISCLOSURES Montegaard: Pharmacyclics: Consultancy; Janssen: Consultancy. Jacobson:Kite, a Gilead Company: Consultancy, Honoraria… 
2019
2019
Factor VIII (FVIII) is indicated for the prevention or treatment of bleeding in patients with hemophilia A. FVIII product… 
Review
2017
Review
2017
Direct oral anticoagulant (DOAC) use is increasing worldwide. However, if not taken or prescribed correctly, DOACs have serious… 
2016
2016
Abstract We present 25-year experience with inhibitors in previously untreated patients (PUPs) with severe hemophilia A in… 
Review
2015
Review
2015
Among adults undergoing non‐cardiac surgery who are at risk of a myocardial infarction, a long‐standing question has been whether… 
Review
2014
Review
2014
Patients with haemophilia A (and their physicians) may be reluctant to switch factor VIII (FVIII) concentrates, often due to… 
Review
2014
Review
2014
Introduction: Antiepileptic drug (AED) teratogenicity is suspected to be the main cause of impaired development in children of… 
Review
2013
Review
2013
Emergency stroke care has become a natural part of the emerging discipline of neurocritical care and demands close cooperation… 
2012
2012
Summary.  On‐demand therapy with recombinant activated factor VII (rFVIIa) can provide effective haemostasis for spontaneous… 
Review
2009
Review
2009
OBJECTIVE TNF receptor 1-associated periodic syndrome (TRAPS) is a rare disease belonging to the heterogeneous group of…